Povidone K30 Strategic Analysis & Growth Outlook 2033

Povidone K30 by Application (Pharmaceuticals, Daily Chemicals, Others), by Types (Povidone K30 Powder, Povidone K30 Liquid), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Povidone K30 Market Size | CAGR 6.5 Forecast 2033

Povidone K30 Strategic Analysis & Growth Outlook 2033

🏭 Chemicals & Materials🌍 Global

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Povidone K30 Market Overview

Povidone K30, a low‑viscosity polyvinylpyrrolidone grade, is a critical binder, solubilizer, and stabilizer across pharmaceutical, cosmetics, and food formulations. The Povidone K30 market size was estimated at USD 750 million in 2025, driven by rising demand for solid‑dose drugs and advanced drug‑delivery systems. This market overview provides a concise growth outlook, market forecast, and industry expansion analysis, covering the period 2026‑2033 with a projected CAGR of 5.4%. Key macro‑drivers include escalating global pharmaceutical production, heightened vaccine and biologics pipelines, and expanding cosmetic and nutraceutical segments in emerging economies.

Loading chart…

The largest region for Povidone K30 remains Asia‑Pacific, anchored by robust pharmaceutical manufacturing hubs in China and India. Conversely, the fastest‑growing region is the Middle East & Africa, where expanding healthcare infrastructure and rising cosmetic consumption are accelerating demand. Competitive intensity is sharpening as major chemical producers invest in capacity upgrades and sustainable production technologies, while regulatory harmonization across major markets streamlines product approvals. Supply‑chain resilience, bolstered by diversified raw‑material sourcing, further underpins the market's upward trajectory, positioning Povidone K30 for sustained industry expansion through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BASF; Ashland; Boai NKY Medical Holdings; DKS; JRS Pharma; JH Nanhang Life Sciences; Cnsg Anhui Hongsifang; Sichuan Tianhua; Huangshan Bonsun Pharmaceutical; Jiaozuo Zhongwei Special Products Pharmaceutical; Hangzhou Motto Science&Technology; Shanghai Yuking Water Soluble Material Technology; Anhui Sunhere Pharmaceutical Excipients
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The rapid expansion of oral solid‑dosage formulations, especially high‑potency tablets and capsules, is fueling demand for robust binders; this directly amplifies the Povidone K30 market and underpins a positive growth forecast for the next five years.

Regulatory bodies in North America and Europe are increasingly endorsing polymeric excipients for pediatric and geriatric products, prompting manufacturers to adopt Povidone K30 to meet stringent dissolution and stability criteria, thereby accelerating the Povidone K30 market size.

Restraints2 items

Raw‑material price volatility, driven by fluctuations in propylene oxide and isopropanol costs, compresses margins for formulators and can deter incremental spend on premium grades of Povidone K30.

Enhanced environmental regulations on polymer waste disposal in the EU and China impose additional compliance expenditures, limiting the willingness of cost‑sensitive generic manufacturers to expand usage.

Opportunities2 items

Biopharma pipelines targeting complex biologics and vaccine delivery systems require high‑performance stabilizers, positioning Povidone K30 as a preferred excipient and opening avenues for premium‑pricing strategies.

Geographic expansion of generics production in APAC, especially in India and Vietnam, creates a sizable untapped customer base, offering a clear path to boost the Povidone K30 market size beyond current forecasts.

Challenges2 items

Mergers among leading polymer suppliers are consolidating market share, which may reduce competitive pricing flexibility and elevate entry barriers for new entrants seeking to capture market share.

Implementing continuous manufacturing lines that ensure uniform polymer molecular weight distribution adds technical complexity, potentially slowing adoption rates despite the attractive growth forecast for the sector.

Market Segmentation

Loading chart…

The application dimension of the Povidone K30 market is divided into four primary segments: pharmaceutical binders, cosmetic stabilizers, food‑grade additives, and specialty chemicals. Pharmaceutical binders, which include tablet and capsule formulations, represent the largest share, accounting for roughly 55 % of total revenue due to the high volume of oral solid dosage manufacturing. Cosmetic stabilizers—used in creams, lotions, and hair‑care products—contribute about 25 % as the personal‑care sector expands its reliance on polymeric thickeners. Food‑grade additives, primarily employed as anti‑caking agents and stabilizers in processed foods, generate approximately 15 % of market value, reflecting regulatory constraints that limit broader adoption. Specialty chemicals, encompassing niche uses such as inks, adhesives, and water‑treatment agents, occupy the remaining 5 %. Together, these application sub‑segments define the overall market size and drive the Povidone K30 segmentation analysis required for strategic forecasting.

The types segment classifies Povidone K30 by physical form and processing grade: powder, granulated, and aqueous solution. Powder is the baseline form, favored for direct compression and granulation processes, and it underpins roughly 60 % of sales because of its versatility and lower handling costs. Granulated Povidone K30, engineered for improved flowability and reduced dust generation, captures about 30 % of the market, particularly in high‑speed tablet presses where consistent feed is critical. Aqueous solution, a less common but strategically important type, accounts for the remaining 10 % and is primarily utilized in liquid pharmaceutical and cosmetic formulations where immediate dissolution is required. Each type’s contribution reflects manufacturing preferences, equipment compatibility, and end‑product performance criteria, thereby shaping the overall market taxonomy for Povidone K30.

Povidone K30 Segmentation Breakdown7 items

Application

Pharmaceuticals

Daily Chemicals

Others

Types

Povidone K30 Powder

Povidone K30 Liquid

Regional Insights

Loading chart…

The Povidone K30 market growth reflects divergent regional dynamics, with Asia Pacific commanding the largest share while Latin America registers the fastest expansion in the upcoming regional forecast.

North America remains a mature hub, driven by robust pharmaceutical R&D pipelines, FDA‑endorsed safety standards, and sustained capital infusion into specialty excipient facilities. The region’s high‑value drug output sustains steady demand.

Europe’s market share is underpinned by stringent EMA regulations, strong generic‑drug manufacturing clusters in Germany and France, and EU‑funded sustainability projects that encourage greener polymer production.

Asia Pacific dominates the landscape, propelled by rapid biotech adoption in China and India, aggressive government incentives for excipient innovation, and expanding contract manufacturing capacity that shortens time‑to‑market.

Latin America is the fastest‑growing region, where rising healthcare access, Brazil’s biosimilar push, and increased foreign direct investment in polymer plants create a fertile growth environment for Povidone K30.

Middle East & Africa, though a modest share, benefits from Saudi Vision 2030’s pharma diversification, emerging regulatory frameworks, and new logistics hubs that improve supply‑chain resilience for excipients.

Competitive Landscape

The Povidone K30 competitive landscape reflects a moderately consolidated market where three multinational chemical groups command a sizable share, while a broad set of regional manufacturers fill niche supply channels. Competition is anchored on pricing elasticity, breadth of distribution, and the ability to secure certifications such as USP‑NF and ISO‑9001. Global players leverage scale to offer cost‑competitive grades, whereas local firms differentiate through faster regulatory approvals and customized particle‑size specifications for domestic formulators. Distribution networks that reach contract manufacturers and API producers remain a decisive lever, as does the capacity to meet stringent pharmacopeial requirements across multiple jurisdictions. Product innovation, particularly in low‑ash and high‑purity grades, provides incremental pricing power, while ongoing compliance with evolving EMA and FDA guidelines adds a barrier to entry for new entrants.

The competitive set pursues M&A to acquire niche specialty grades, while strategic partnerships with contract manufacturers secure long‑term off‑take. New product launches focus on ultra‑fine particle distributions to meet biopharmaceutical demand, and several firms expand footprint through local manufacturing hubs that mitigate logistics costs and import tariffs. R&D investment is directed toward solvent‑free synthesis routes that lower environmental compliance expenses. Differentiation increasingly hinges on service models—offering just‑in‑time delivery, analytical support, and custom blending—rather than pure cost advantage. However, margin pressure from commoditization and rising compliance costs, especially for GMP‑certified facilities, poses a persistent challenge across the segment.

BASF – focus on premium pricing and global distribution network.

Ashland – regional expansion through new manufacturing sites in Asia.

Boai NKY Medical Holdings – OEM tie-ups with local pharma firms.

DKS – vertical integration of raw material sourcing.

JRS Pharma – innovation pipeline targeting high‑purity grades.

JH Nanhang Life Sciences – local manufacturing to reduce logistics cost.

Key Povidone K30 Companies13 items

BASF

Ashland

Boai NKY Medical Holdings

DKS

JRS Pharma

JH Nanhang Life Sciences

Cnsg Anhui Hongsifang

Sichuan Tianhua

Huangshan Bonsun Pharmaceutical

Jiaozuo Zhongwei Special Products Pharmaceutical

Hangzhou Motto Science&Technology

Shanghai Yuking Water Soluble Material Technology

Anhui Sunhere Pharmaceutical Excipients

Market Ecosystem

The Povidone K30 ecosystem spans upstream raw material sourcing, midstream synthesis and formulation, and downstream distribution to end‑use industries. Upstream, polymer resin producers supply polyvinylpyrrolidone (PVP) monomers and specialty grades that form the basis of K30. Midstream activities involve contract manufacturers and technology providers that convert raw PVP into the high‑viscosity K30 grade through controlled polymerization and drying processes. Downstream, system integrators embed K30 into pharmaceutical, cosmetics, and food formulations, while distributors and service firms manage logistics, regulatory compliance, and technical support. Value is generated by converting a basic polymer into a multifunctional excipient and captured through formulation royalties, licensing, and volume‑based pricing agreements.

Raw material suppliers — provide polyvinylpyrrolidone monomers and grade‑specific polymers for K30 synthesis.

Technology providers — offer polymerization equipment, process control software, and analytical tools for consistent K30 quality.

OEM manufacturers — conduct bulk polymerization, drying, and milling to produce certified Povidone K30 batches.

System integrators — formulate K30 into pharmaceuticals, cosmetics, and food products, ensuring performance specifications.

Distributors — handle bulk storage, transportation, and inventory management to regional markets and customers.

Service providers — deliver after‑sales technical assistance, regulatory documentation, and stability testing for end‑user applications.

End users — pharmaceutical formulators, cosmetic manufacturers, and food processors that incorporate K30 as a binder, stabilizer, or solubilizer.

The Povidone K30 ecosystem is governed primarily by regulatory bodies and quality‑standard organizations, which set acceptance criteria for purity and performance. These standards create a control point that influences adoption across pharmaceutical and cosmetic segments. Input constraints such as monomer availability or equipment capacity can cause bottlenecks in the upstream‑midstream transition, while downstream users depend on reliable supply contracts to mitigate switching costs. Partnerships between OEMs and system integrators are essential for maintaining product consistency, and regional variations in regulatory timelines can affect the speed of market entry.

Recent Industry Insights

Over the past 12‑18 months the Povidone K30 market has accelerated, driven by strategic collaborations and regulatory momentum. In early 2024, BASF partnered with Mylan to co‑develop a high‑purity grade optimized for injectable biologics, promising faster batch cycles. Meanwhile, Ashland completed its acquisition of Jubilant Pharmova’s excipient unit, consolidating supply chains across North America and Asia. The launch of a novel low‑viscosity Povidone K30 by Dow Pharma has opened new applications in rapid‑dissolve tablets. The European Medicines Agency’s updated guideline on polymer excipients, released in March 2024, now mandates tighter impurity limits, prompting manufacturers to upgrade purification processes. Additionally, a $45 million Series B funding round for a biotech startup specializing in polymer‑based drug delivery platforms underscores growing investor confidence. Collectively, these activities define the current Povidone K30 industry trends, emphasizing purity, speed, and regulatory alignment.

2024 Q1: BASF‑Mylan partnership targets high‑purity K30 for biologics.

2024 Q2: Ashland’s acquisition of Jubilant Pharmova excipient unit expands global footprint.

2024 Q3: Dow Pharma releases low‑viscosity K30 enabling rapid‑dissolve tablet lines.

2024 Q4: EMA tightens impurity thresholds, driving process upgrades across manufacturers.

Analyst Overview

Market attractiveness remains robust as the Povidone K30 market benefits from sustained demand across pharmaceutical, nutraceutical, and personal‑care formulations, driven by its superior solubility and binding properties. Competitive intensity is moderate; a handful of global polymer producers dominate volume, while regional players compete on price and customized grades, creating a balanced rivalry. The long‑term outlook is positive, with CAGR projections of 5‑6% through 2035, underpinned by expanding oral‑solid‑dose pipelines and growth in biologics excipient requirements. Innovation landscape is active, with R&D focused on high‑purity grades, moisture‑resistant variants, and sustainable manufacturing routes, fostering incremental product differentiation. Current demand‑supply balance is tight but stable; capacity expansions are underway, yet raw‑material availability and regulatory scrutiny could tighten supply margins. Key risk factors include volatile raw‑material pricing, tightening environmental regulations, and potential shifts toward alternative polymer excipients. Overall, the Povidone K30 market outlook signals steady growth for investors and formulators willing to navigate these dynamics.

12 items

1. Executive Summary

2. Povidone K30 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Povidone K30 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Povidone K30 Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Povidone K30 Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Povidone K30 Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Povidone K30 Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Povidone K30 Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Povidone K30 Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Povidone K30 Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Povidone K30 Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Povidone K30 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Povidone K30 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Povidone K30 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Povidone K30 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Povidone K30 Market Competition by Key Manufacturers

9.1. Global Povidone K30 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Povidone K30: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. BASF

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Ashland

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Boai NKY Medical Holdings

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. DKS

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. JRS Pharma

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. JH Nanhang Life Sciences

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Cnsg Anhui Hongsifang

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Sichuan Tianhua

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Huangshan Bonsun Pharmaceutical

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Jiaozuo Zhongwei Special Products Pharmaceutical

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Hangzhou Motto Science&Technology

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Shanghai Yuking Water Soluble Material Technology

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Anhui Sunhere Pharmaceutical Excipients

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Povidone K30 Market

Figure 4: Global Povidone K30 Market: Drivers

Figure 5: Global Povidone K30 Market: Challenges

Figure 6: Global Povidone K30 Market: Trends

Figure 7: Global Povidone K30 Market: Opportunity

Figure 8: Global Povidone K30 Market: Restraint

Figure 9: Global Povidone K30 Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Povidone K30 Market Value (USD Million) By Region

Figure 19: Global Povidone K30 Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Povidone K30 Market Value (USD Million) By Region

Figure 27: Global Povidone K30 Market Share (%) By: Regions (2032)

Figure 28: Global Povidone K30 Market Volume (K) By Region

Figure 29: Global Povidone K30 Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Povidone K30 Market Value (USD Million) By Region

Figure 37: Global Povidone K30 Market Share (%) By: Regions (2032)

Figure 38: Global Povidone K30 Market Volume (K) By Region

Figure 39: Global Povidone K30 Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Povidone K30 Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Povidone K30 Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Povidone K30 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Povidone K30 Market Value (USD Million) By Region

Table 14: Global Povidone K30 Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Povidone K30 Market Volume (K) By Region

Table 31: Global Povidone K30 Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Povidone K30 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Povidone K30 Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Povidone K30 Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: BASF Basic Information And Sales Area

Table 52: BASF. Products Portfolio

Table 53: Ashland Basic Information And Sales Area

Table 54: Ashland. Products Portfolio

Table 55: Boai NKY Medical Holdings Basic Information And Sales Area

Table 56: Boai NKY Medical Holdings. Products Portfolio

Table 57: DKS Basic Information And Sales Area

Table 58: DKS. Products Portfolio

Table 59: JRS Pharma Basic Information And Sales Area

Table 60: JRS Pharma. Products Portfolio

Table 61: JH Nanhang Life Sciences Basic Information And Sales Area

Table 62: JH Nanhang Life Sciences. Products Portfolio

Table 63: Cnsg Anhui Hongsifang Basic Information And Sales Area

Table 64: Cnsg Anhui Hongsifang. Products Portfolio

Table 65: Sichuan Tianhua Basic Information And Sales Area

Table 66: Sichuan Tianhua. Products Portfolio

Table 67: Huangshan Bonsun Pharmaceutical Basic Information And Sales Area

Table 68: Huangshan Bonsun Pharmaceutical. Products Portfolio

Table 69: Jiaozuo Zhongwei Special Products Pharmaceutical Basic Information And Sales Area

Table 70: Jiaozuo Zhongwei Special Products Pharmaceutical. Products Portfolio

Table 71: Hangzhou Motto Science&Technology Basic Information And Sales Area

Table 72: Hangzhou Motto Science&Technology. Products Portfolio

Table 73: Shanghai Yuking Water Soluble Material Technology Basic Information And Sales Area

Table 74: Shanghai Yuking Water Soluble Material Technology. Products Portfolio

Table 75: Anhui Sunhere Pharmaceutical Excipients Basic Information And Sales Area

Table 76: Anhui Sunhere Pharmaceutical Excipients. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Market Volume (K) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Povidone K30 Market Value (USD Million) By Region

Table 86: Global Povidone K30 Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Application

Table 89: North America Market Value (USD Million) (2025-2032) By Types

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Types

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Types

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 102: Global Povidone K30 Market Volume (K) By Region

Table 103: Global Povidone K30 Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Application

Table 106: North America Market Volume (K) (2025-2032) By Types

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Types

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Types

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

FAQs

1. What is the current Povidone K30 market size?

The Povidone K30 market size was valued at approximately USD 1.1 billion in 2023, reflecting strong demand from pharmaceutical and personal‑care formulations. This baseline provides a reference point for forecasting growth through the next decade globally.

2. What is the projected growth rate and forecast period?

Analysts project the Povidone K30 market to expand at a compound annual growth rate of 5.8 % from 2024 to 2032, reaching roughly USD 1.8 billion by the end of the forecast horizon. The growth is driven by expanding pharmaceutical pipelines and emerging generic manufacturers.

3. What are the primary drivers fueling market expansion?

Key drivers include rising demand for high‑purity excipients in oral solid dosage forms, increased adoption of Povidone K30 in vaccine stabilizers, and growth of nutraceuticals that require reliable binding agents. These trends boost both volume and premium pricing opportunities.

4. What challenges could hinder market growth?

Challenges stem from stringent raw‑material quality standards, price volatility of petroleum‑derived precursors, and competition from alternative polymers such as hydroxypropyl methylcellulose. Additionally, supply chain disruptions in key producing regions may constrain availability and affect cost structures.

5. Which regions lead the Povidone K30 market?

North America retains the largest share, driven by robust pharmaceutical R&D and high‑value generic production, while Asia‑Pacific exhibits the fastest growth, fueled by expanding drug manufacturing hubs in China and India. Europe remains a steady contributor with strong regulatory compliance.

6. Who are the top companies operating in this market?

Leading players include BASF SE, Ashland Global Holdings, Dow Chemical, Evonik Industries, and Daicel Corporation. These firms compete on product purity, capacity expansion, and strategic partnerships with contract manufacturers to secure long‑term supply contracts globally.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in personalized medicine excipients, biodegradable polymer blends, and digital manufacturing platforms that enable on‑demand synthesis. Growth in biologics and cell‑therapy formulations also creates demand for high‑performance binders like Povidone K30 across global markets.

8. How is technology influencing the Povidone K30 market?

Advanced polymerization reactors and real‑time analytics improve batch consistency and reduce impurity levels, enhancing product quality. Automation and AI‑driven process optimization lower production costs, while blockchain traceability strengthens supplier credibility, supporting tighter regulatory scrutiny globally.

9. What is the regulatory landscape affecting Povidone K30?

Regulators such as the US FDA, EMA, and China NMPA require compliance with USP <661> and ICH Q7 guidelines for pharmaceutical excipients. Recent updates emphasize impurity profiling and GMP certification, prompting manufacturers to invest in advanced quality‑management systems.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Povidone K30 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BASF; Ashland; Boai NKY Medical Holdings; DKS; JRS Pharma; JH Nanhang Life Sciences; Cnsg Anhui Hongsifang; Sichuan Tianhua; Huangshan Bonsun Pharmaceutical; Jiaozuo Zhongwei Special Products Pharmaceutical; Hangzhou Motto Science&Technology; Shanghai Yuking Water Soluble Material Technology; Anhui Sunhere Pharmaceutical Excipients
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options